March 2023 FDA Recall Aripiprazole by Ascend Laboratories, Llc (D-0539-2023 - Out of specification (OOS) for Spectroscopic Identification test by IR.)

This Class II drug recall was voluntarily initiated by Ascend Laboratories, Llc on March 17, 2023 for the product Aripiprazole. The FDA reported the reason for recall as out of specification (oos) for spectroscopic identification test by ir.. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0539-2023

Reason for Recall
Out of specification (OOS) for Spectroscopic Identification test by IR.
Initiated
03-17-2023
Reported
04-26-2023
Quantity
135 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Ascend Laboratories, LLC
Nationwide in the USA
Aripiprazole Tablets, USP, 20 mg, Rx Only, Packaged in 500-count bottle Manufactured by: Alkem Laboratories Ltd., INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC#: 67877-434-05

Batch or Lot Expiration Information

Lot# 22143120, Exp. Date: June 2024